Weight, glucose, and metabolic health
This is where the mechanism meets the measured result. Retatrutide two flagship phase 2 trials, an obesity study in the…
What the phase 2 obesity and diabetes trials actually showed
This is where the mechanism meets the measured result. Retatrutide two flagship phase 2 trials, an obesity study in the New England Journal of Medicine and a type 2 diabetes study in The Lancet, are the strongest evidence the drug has, and they report large, dose-dependent effects on weight and blood sugar.
This unit reads those numbers carefully and honestly: how big the effects were, how they scaled with dose, and where the limits of a 48-week phase 2 readout lie. These are real human randomized results, the green tier of the evidence map, and they deserve a close, plain look.
Key terms
The obesity trial, dose by dose
The headline phase 2 obesity result is not a single number but a staircase: each higher dose produced more weight loss, all the way to about 24% at 48 weeks on the top dose. A clear dose-response like this is one of the strongest hints that an effect is real and drug-driven, not chance.
The curve flattens a little at the top but is still climbing at the highest dose tested, which is part of why higher-dose and longer phase 3 trials are so anticipated. Remember the placebo group lost only about 2%, so almost all of this staircase is genuine drug effect.
AdvancedWhy dose-response builds confidence
A clean dose-response, more drug giving more effect in an orderly way, is a classic signature of a real pharmacological effect. It is much harder to explain by bias or chance than a single positive number, which is why trialists prize it.